Cargando…
Combination Strategies to Augment Immune Check Point Inhibitors Efficacy - Implications for Translational Research
Immune checkpoint inhibitor therapy has revolutionized the field of cancer immunotherapy. Even though it has shown a durable response in some solid tumors, several patients do not respond to these agents, irrespective of predictive biomarker (PD-L1, MSI, TMB) status. Multiple preclinical, as well as...
Autores principales: | Varayathu, Hrishi, Sarathy, Vinu, Thomas, Beulah Elsa, Mufti, Suhail Sayeed, Naik, Radheshyam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8193928/ https://www.ncbi.nlm.nih.gov/pubmed/34123767 http://dx.doi.org/10.3389/fonc.2021.559161 |
Ejemplares similares
-
Addition of Nimotuzumab to Standard TPF Regimen in Locally Advanced Head and Neck Cancer: A Single Institutional Study
por: Koramati, Samuel Luke, et al.
Publicado: (2021) -
Ogilvie Syndrome in a Refractory Germ Cell Tumor Treated with Vinblastine, Ifosfamide and Cisplatin Regimen
por: Varayathu, Hrishi, et al.
Publicado: (2020) -
Study of Peripheral Mononuclear Cells and CD34 Levels as a Predictive Marker for Initiating Apheresis in Autologous Stem Cell Transplant
por: Pura Krishnamurthy, Kiran, et al.
Publicado: (2021) -
Hypermagnesemia in critically ill patients with cancer: A case report
por: Krupesh, Vijay Raju, et al.
Publicado: (2021) -
An Update on Advances in COVID-19 Laboratory Diagnosis and Testing Guidelines in India
por: Kumar, K. S. Rajesh, et al.
Publicado: (2021)